An open-label phase II study of intermittent oral capecitabine (X) as first-line treatment for patients (pts) with metastatic colorectal cancer (MCRC)

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Oral Capecitabine ◽

Open Label Phase ◽

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70330-4 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1065-1075 ◽

Cited By ~ 881

Author(s):

Volker Heinemann ◽

Ludwig Fischer von Weikersthal ◽

Thomas Decker ◽

Alexander Kiani ◽

Ursula Vehling-Kaiser ◽

...

Keyword(s):

Colorectal Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study

BMC Cancer ◽

10.1186/1471-2407-10-567 ◽

2010 ◽

Vol 10 (1) ◽

Cited By ~ 33

Author(s):

Gemma Bruera ◽

Alessandra Santomaggio ◽

Katia Cannita ◽

Paola Lanfiuti Baldi ◽

Marianna Tudini ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma

Investigational New Drugs ◽

10.1007/s10637-018-0599-4 ◽

2018 ◽

Vol 36 (4) ◽

pp. 674-682 ◽

Cited By ~ 1

Author(s):

Arthur Lui ◽

Karen Mulder ◽

Christine Brezden-Masley ◽

Michael Vickers ◽

Jose Monzon ◽

...

Keyword(s):

Phase Ii ◽

Phase Ii Study ◽

Gastroesophageal Junction ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Phase ◽

Randomized phase II study of FOLFIRI plus ramucirumab (Rmab) versus FOLFOXIRI plus Rmab as first-line treatment for patients with metastatic colorectal cancer (mCRC): WJOG9216G

Annals of Oncology ◽

10.1093/annonc/mdy281.151 ◽

2018 ◽

Vol 29 ◽

pp. viii201

Author(s):

Y. Kito ◽

T. Yamada ◽

T. Matsumoto ◽

H. Yasui ◽

K. Murata ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

British Journal of Cancer ◽

10.1038/sj.bjc.6603493 ◽

2007 ◽

Vol 96 (3) ◽

pp. 439-444 ◽

Cited By ~ 21

Author(s):

E Bajetta ◽

◽

M Di Bartolomeo ◽

R Buzzoni ◽

L Mariani ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Colorectal Cancer Patients ◽

A phase II study of biweekly irinotecan (CPT-11) and 5-fluorouracil (5-FU) as first line treatment in advanced or metastatic colorectal cancer (CRC)

European Journal of Cancer ◽

10.1016/s0959-8049(01)81582-3 ◽

2001 ◽

Vol 37 ◽

pp. S295-S296 ◽

Cited By ~ 1

Author(s):

J. Salvador ◽

R. Bernabe ◽

M. Bolaños ◽

P. Borrega ◽

M. Valladares ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

‘A phase II study of oral uracil/ftorafur (UFT®) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer’

British Journal of Cancer ◽

10.1038/sj.bjc.6602913 ◽

2005 ◽

Vol 94 (1) ◽

pp. 69-73 ◽

Cited By ~ 12

Author(s):

J Bennouna ◽

H Perrier ◽

B Paillot ◽

F Priou ◽

J H Jacob ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

An Open‐Label Phase II Study Evaluating the Safety and Efficacy of Ramucirumab Combined With mFOLFOX‐6 as First‐Line Therapy for Metastatic Colorectal Cancer

The Oncologist ◽

10.1634/theoncologist.2014-0028 ◽

2014 ◽

Vol 19 (4) ◽

pp. 350-351 ◽

Cited By ~ 37

Author(s):

Rocio Garcia‐Carbonero ◽

Fernando Rivera ◽

Joan Maurel ◽

Jean‐Pierre M. Ayoub ◽

Malcolm J. Moore ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

First Line ◽

Open Label ◽

Safety And Efficacy ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.3658 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 3658-3658

Author(s):

T. H. Cartwright ◽

T. Lopez ◽

S. J. Vukelja ◽

C. Encarnacion ◽

K. A. Boehm ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.4031 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 4031-4031 ◽

Cited By ~ 12

Author(s):

A. Falcone ◽

G. Masi ◽

F. Loupakis ◽

E. Vasile ◽

A. Ciarlo ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽